The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Incubator/Accelerator | Alive

About Cardiosense

Cardiosense develops a wireless wearable to deliver ICU-level visibility into heart function, monitoring trends to predict deterioration, and uses insights to guide personalized treatment.

Cardiosense Headquarters Location

222 W Merchandise Mart Plaza #1230

Chicago, Illinois, 60654,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cardiosense

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cardiosense is included in 4 Expert Collections, including Medical Devices.


Medical Devices

8,453 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.



2,839 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.


Health Monitoring & Diagnostics

1,300 items

Companies developing wearable health monitoring solutions (human health only). Companies tagged as #Wearables (*note: this tag may also apply to companies outside the scope of this collection)


Health IT

8,876 items

Cardiosense Patents

Cardiosense has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Kidney anatomy, Cardiovascular physiology, Angiology, Medical equipment, String theory


Application Date


Grant Date



Related Topics

Kidney anatomy, Cardiovascular physiology, Angiology, Medical equipment, String theory



Latest Cardiosense News

11:00 ET Cardiosense receives FDA Breakthrough Device designation for algorithm to identify patients at risk of decompensated he...

Feb 15, 2022

News provided by Share this article Share this article CHICAGO, Feb. 15, 2022 /PRNewswire/ -- Cardiosense, Inc. , a Chicago-based digital health company building a physiological waveform AI platform to manage cardiac disease, announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device status for its novel algorithm to identify patients at risk of decompensated heart failure. The algorithm analyzes data collected from the multi-sensor CardioTag device to noninvasively assess pulmonary capillary wedge pressure (PCWP), a measure that currently can only be captured through an invasive catheterization procedure. The FDA Breakthrough Device designation will enable expedited regulatory review of the algorithm and is only awarded to breakthrough technologies that have the potential to provide more effective treatment and diagnosis for life-threatening or irreversible debilitating diseases or conditions. "The Breakthrough Device designation recognizes our platform's potential to address one of the biggest unmet clinical needs in managing heart failure," said Amit Gupta, CEO and a co-founder of Cardiosense. "The fact is there are clear physiological changes that occur well before an acute heart failure event, and we look forward to working with the FDA to deliver a noninvasive solution to identify them." Cardiosense's platform is built on over a decade of research led by Omer Inan, Ph.D., Linda J. and Mark C. Smith Chair in Bioscience and Bioengineering at Georgia Institute of Technology, and Mozziyar Etemadi, M.D., Ph.D., Medical Director, Advanced Technologies at Northwestern Medicine. "We've combined noninvasive sensors and industry-leading AI to develop digital biomarkers for early disease detection and to guide therapy," said Dr. Inan, who is also a co-founder of Cardiosense. "CardioTag, the company's proprietary wearable device captures high-fidelity, multi-modal physiological signals that are analyzed to assess cardiac function parameters that typically require invasive devices only available in intensive care settings." Cardiosense's technology can have a particularly strong impact in heart failure. More than 6 million patients in the US live with heart failure, leading to over 1 million hospitalizations annually. Despite current best practice guidelines, including regular physical exams in clinic and daily weight monitoring, nearly 50% of patients are re-hospitalized within 6 months of a heart failure hospitalization. An increase in cardiac filling pressures, assessed using PCWP, often precedes clinical symptoms by several weeks but currently requires an invasive catheterization procedure to measure. The CardioTag device, coupled with Cardiosense's novel algorithm, is addressing this gap with the capability to assess PCWP in any setting, enabling care providers to identify early signs of acute heart failure, implement therapeutic interventions, and avoid hospitalizations. The Breakthrough Device designation was supported in part by National Institutes of Health funded research led by Dr. Liviu Klein, M.D., M.S., Section Chief, Advanced Heart Failure, Mechanical Circulatory Support, Pulmonary Hypertension & Heart Transplantation at UCSF and Lead Clinical Advisor at Cardiosense, in collaboration with Dr. Inan and Dr. Etemadi. "Cardiosense's technology has the potential to be a revolutionary advance in the noninvasive assessment of the hemodynamic state of patients with heart failure," said Dr. Klein. "One of the greatest challenges in the management of patients with chronic heart failure is forecasting and preventing the development of acute worsening leading to hospitalizations. This technology could be used to identify time periods at risk and opportunities for intervention for patients with heart failure." About Cardiosense Cardiosense is building a physiological waveform AI platform to develop predictive biomarkers to detect and manage cardiac disease. The company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms for use by care providers to detect clinical worsening earlier, inform personalized therapy, and improve patient outcomes. For more information, visit: . About the FDA Breakthrough Device Program The FDA Breakthrough Device program enables expedited regulatory assessment of novel technologies with the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The goal of the Breakthrough Devices Program is to provide patients and health care providers with timely access to these medical devices by speeding up their development, assessment, and review, while preserving the statutory standards for premarket approval, 510(k) clearance, and De Novo marketing authorization, consistent with the Agency's mission to protect and promote public health. Related Links

  • When was Cardiosense founded?

    Cardiosense was founded in 2020.

  • Where is Cardiosense's headquarters?

    Cardiosense's headquarters is located at 222 W Merchandise Mart Plaza, Chicago.

  • What is Cardiosense's latest funding round?

    Cardiosense's latest funding round is Incubator/Accelerator.

  • Who are the investors of Cardiosense?

    Investors of Cardiosense include MedTech Innovator.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.